What the experts say

Give Big Pharma a chance; Taxes: Go it alone or hire a pro?; Trim your grocery bill

Give Big Pharma a chance

Investors usually flock to pharmaceutical stocks when the economy is under the weather, said Conrad De Aenlle in The New York Times. But recently the sector has been dragged down by generic competition and talk of health-care reform. Still, some experts say all this creates a buying opportunity. “Most of these companies are trading at very low multiples of earnings,” says Damien Conover, an analyst at Morningstar. Merck stock, still reeling from bad news about its cholesterol drug Vytorin, now trades at just 12 times earnings—a valuation that underestimates Merck’s tried-and-true cardiovascular and diabetes drugs. Pfizer trades at less than 10 times its 2008 estimated earnings, and has a 5 percent dividend yield to boot. Other deals can be identified throughout the sector, according to Barry Ogden, manager of the Ivy Capital Appreciation fund. “At these valuations, you’ve got to be predisposed to build positions in some of these names,” Ogden says.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up